Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safusidenib in advanced IDH1 mutant solid tumors
NCT05814536Phase 1Terminated
- Sponsor
- AnHeart Therapeutics
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of safusidenib in cholangiocarcinoma (CCA) and solid tumor, sponsored by AnHeart Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 24 months and Dose Limiting Toxicity at 28 days. Started May 2023; status: terminated.
02
Drugs
safusidenib
03
Conditions
cholangiocarcinoma (CCA)solid tumor
Beyond the preview
Go deeper on NCT05814536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814536.